NGENLA Solution for injection Ref.[49626] Active ingredients: Somatrogon

Source: European Medicines Agency (EU)  Revision Year: 2022  Publisher: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Product name and form

Ngenla 24 mg solution for injection in pre-filled pen.

Ngenla 60 mg solution for injection in pre-filled pen.

Pharmaceutical Form

Solution for injection (injection).

The solution is a clear and colourless to slightly light yellow solution with a pH of 6.6.

Qualitative and quantitative composition

Ngenla 24 mg solution for injection in pre-filled pen:

One mL of solution contains 20 mg of somatrogon*.

Each pre-filled pen contains 24 mg somatrogon in 1.2 mL solution.

Each pre-filled pen delivers doses from 0.2 mg to 12 mg in a single injection in 0.2 mg increments.

Ngenla 60 mg solution for injection in pre-filled pen:

One mL of solution contains 50 mg of somatrogon.

Each pre-filled pen contains 60 mg somatrogon in 1.2 mL solution.

Each pre-filled pen delivers doses from 0.5 mg to 30 mg in a single injection in 0.5 mg increments.

* Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Somatrogon

Somatrogon is a glycoprotein comprised of the amino acid sequence of hGH with one copy of the of C-terminal peptide (CTP) from the beta chain of human chorionic gonadotropin (hCG) at the N-terminus and two copies of CTP (in tandem) at the C-terminus. The glycosylation and CTP domains account for the half-life of somatrogon, which allows for weekly dosing. Somatrogon binds to the GH receptor and initiates a signal transduction cascade culminating in changes in growth and metabolism.

List of Excipients

Trisodium citrate dihydrate
Citric acid monohydrate
L-Histidine
Sodium chloride
m-Cresol
Poloxamer 188
Water for injections

Pack sizes and marketing

Ngenla 24 mg solution for injection in pre-filled pen

This multi-dose disposable pre-filled pen, which consists of a cartridge (Type I clear glass) permanently sealed in a plastic pen, contains 1.2 mL of somatrogon. The cartridge is closed at the bottom with a rubber stopper (Type I rubber closures) shaped as a plunger and at the top with a rubber stopper (Type I rubber closures) shaped as a disc and sealed with an aluminium cap. The pen cap, dose button and label on the pen are coloured lilac.

Pack size of 1 pre-filled pen.

Ngenla 60 mg solution for injection in pre-filled pen

This multi-dose disposable pre-filled pen, which consists of a cartridge (Type I clear glass) permanently sealed in a plastic pen, contains 1.2 mL of somatrogon. The cartridge is closed at the bottom with a rubber stopper (Type I rubber closures) shaped as a plunger and at the top with a rubber stopper (Type I rubber closures) shaped as a disc and sealed with an aluminium cap. The pen cap, dose button and label on the pen are coloured blue.

Pack size of 1 pre-filled pen.

Marketing authorization holder

Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Marketing authorization dates and numbers

EU/1/21/1617/001
EU/1/21/1617/002

Drugs

Drug Countries
NGENLA Canada, Estonia, Croatia, Italy, Japan, Poland, Romania, Turkey

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.